Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS).
Schiweck, Nicole, Langer, Katharina, Maier, Andrea et al. · Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026 · DOI
Quick Summary
This review examined treatments for POTS (postural orthostatic tachycardia syndrome), a condition where your heart rate jumps significantly when you stand up, causing dizziness and fatigue. POTS is common in people with ME/CFS. The researchers looked at 45 studies and found that simple first-line treatments like compression socks, physical training, extra salt, and a vagus nerve stimulation device may help, while certain medications like ivabradine and beta-blockers also showed promise in some studies.
Why It Matters
Since POTS affects a substantial proportion of ME/CFS patients and contributes significantly to symptom burden and disability, this systematic review provides clinicians and patients with an evidence-based summary of available treatment options. For ME/CFS patients, understanding which POTS treatments have support may help guide clinical conversations and treatment planning, particularly since POTS management can improve functional capacity and quality of life.
Observed Findings
Compression garments, physical training, salt supplementation, and transdermal vagal nerve stimulation were identified as implementable first-line non-pharmacological approaches in clinical practice.
Ivabradine and β-adrenergic blocking agents demonstrated significant effects in several studies.
Midodrine hydrochloride and pyridostigmine showed beneficial hemodynamic effects in single or limited studies.
Only 45 of 3,853 identified studies met inclusion criteria, indicating severe evidence scarcity.
Large randomized controlled trials specifically comparing single interventions are lacking.
Inferred Conclusions
Non-pharmacological treatments are practical starting points because they are accessible and carry minimal risk, making them suitable for first-line use in POTS management.
Pharmacological options like ivabradine and beta-blockers have emerging evidence support but require larger trials to establish efficacy and optimal use.
There is an urgent need for high-quality randomized controlled trials evaluating POTS treatments, particularly in pediatric and ME/CFS populations where evidence is most limited.
Remaining Questions
Which POTS treatments are most effective specifically for ME/CFS patients, and do they differ from the general POTS population?
What This Study Does Not Prove
This review does not establish which treatments are most effective for ME/CFS-specific POTS, as evidence in this population remains sparse. It does not prove that individual treatments work universally across all patients, as responses are highly variable. The review also cannot determine optimal dosing, duration, or combination therapies due to limited comparative data.
Tags
Symptom:Orthostatic IntoleranceFatigue
Phenotype:Pediatric
Method Flag:Weak Case DefinitionExploratory OnlyMixed Cohort